{"transactions":[{"id":312737,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-26T23:01:56.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":945,"price":486.35,"value":459600.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025."}],"balance_after":13659,"source":{"system":"sec-edgar","filing":"0000875320-26-000108","document":"wk-form4_1772146913.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000108/wk-form4_1772146913.xml","form_type":"4"}},{"id":312736,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-26T23:01:56.000Z","date":"2026-02-24","kind":"tax_withholding","planned":true,"acquired":false,"shares":1144,"price":485.11,"value":554965.84,"ownership":{"direct":true},"balance_after":14604,"source":{"system":"sec-edgar","filing":"0000875320-26-000108","document":"wk-form4_1772146913.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000108/wk-form4_1772146913.xml","form_type":"4"}},{"id":313149,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-19T21:08:39.000Z","date":"2026-02-18","kind":"sale","planned":true,"acquired":false,"shares":1244,"price":473.68,"value":589257.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025."}],"balance_after":15748,"source":{"system":"sec-edgar","filing":"0000875320-26-000084","document":"wk-form4_1771535316.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000084/wk-form4_1771535316.xml","form_type":"4"}},{"id":313148,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-19T21:08:39.000Z","date":"2026-02-17","kind":"sale","planned":true,"acquired":false,"shares":2476,"price":489.46,"value":1211902.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025."}],"balance_after":16992,"source":{"system":"sec-edgar","filing":"0000875320-26-000084","document":"wk-form4_1771535316.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000084/wk-form4_1771535316.xml","form_type":"4"}},{"id":313147,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-19T21:08:39.000Z","date":"2026-02-17","kind":"tax_withholding","planned":true,"acquired":false,"shares":1505,"price":483.75,"value":728043.75,"ownership":{"direct":true},"balance_after":19468,"source":{"system":"sec-edgar","filing":"0000875320-26-000084","document":"wk-form4_1771535316.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000084/wk-form4_1771535316.xml","form_type":"4"}},{"id":313146,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-19T21:08:39.000Z","date":"2026-02-17","kind":"grant","planned":true,"acquired":true,"shares":4135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests in installments beginning on February 20, 2027."}],"balance_after":20973,"source":{"system":"sec-edgar","filing":"0000875320-26-000084","document":"wk-form4_1771535316.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000084/wk-form4_1771535316.xml","form_type":"4"}},{"id":313479,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:26:14.000Z","date":"2026-02-13","kind":"sale","planned":true,"acquired":false,"shares":988,"price":499,"value":493012.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025."}],"balance_after":16838,"source":{"system":"sec-edgar","filing":"0000875320-26-000064","document":"wk-form4_1771449971.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000064/wk-form4_1771449971.xml","form_type":"4"}},{"id":313478,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:26:14.000Z","date":"2026-02-13","kind":"tax_withholding","planned":true,"acquired":false,"shares":2993,"price":487.76,"value":1459865.68,"ownership":{"direct":true},"balance_after":17826,"source":{"system":"sec-edgar","filing":"0000875320-26-000064","document":"wk-form4_1771449971.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000064/wk-form4_1771449971.xml","form_type":"4"}},{"id":313867,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-12T21:52:20.000Z","date":"2026-02-11","kind":"sale","planned":true,"acquired":false,"shares":1925,"price":460.43,"value":886327.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025."}],"balance_after":20819,"source":{"system":"sec-edgar","filing":"0000875320-26-000040","document":"wk-form4_1770933137.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000040/wk-form4_1770933137.xml","form_type":"4"}},{"id":313866,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-12T21:52:20.000Z","date":"2026-02-10","kind":"tax_withholding","planned":true,"acquired":false,"shares":1630,"price":468.41,"value":763508.3,"ownership":{"direct":true},"balance_after":22744,"source":{"system":"sec-edgar","filing":"0000875320-26-000040","document":"wk-form4_1770933137.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000040/wk-form4_1770933137.xml","form_type":"4"}},{"id":314836,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-01-26T21:20:43.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":2774,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026."}],"balance_after":24374,"source":{"system":"sec-edgar","filing":"0000875320-26-000014","document":"wk-form4_1769462440.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000014/wk-form4_1769462440.xml","form_type":"4"}},{"id":314835,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-01-26T21:20:43.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":6294,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026."}],"balance_after":21600,"source":{"system":"sec-edgar","filing":"0000875320-26-000014","document":"wk-form4_1769462440.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000014/wk-form4_1769462440.xml","form_type":"4"}},{"id":316526,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-12-05T21:06:00.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":347,"price":449,"value":155803.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025."}],"balance_after":15306,"source":{"system":"sec-edgar","filing":"0000875320-25-000240","document":"wk-form4_1764968757.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000240/wk-form4_1764968757.xml","form_type":"4"}},{"id":318318,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-10-03T20:07:18.000Z","date":"2025-10-02","kind":"sale","planned":true,"acquired":false,"shares":694,"price":404.21,"value":280521.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025."}],"balance_after":15653,"source":{"system":"sec-edgar","filing":"0000875320-25-000224","document":"wk-form4_1759522036.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000224/wk-form4_1759522036.xml","form_type":"4"}},{"id":318317,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-10-03T20:07:18.000Z","date":"2025-10-01","kind":"tax_withholding","planned":true,"acquired":false,"shares":1259,"price":400,"value":503600.0,"ownership":{"direct":true},"balance_after":16347,"source":{"system":"sec-edgar","filing":"0000875320-25-000224","document":"wk-form4_1759522036.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000224/wk-form4_1759522036.xml","form_type":"4"}},{"id":325786,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-02-19T21:28:19.000Z","date":"2025-02-18","kind":"sale","planned":true,"acquired":false,"shares":1657,"price":455.06,"value":754034.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/13/2024."}],"balance_after":17606,"source":{"system":"sec-edgar","filing":"0000875320-25-000085","document":"wk-form4_1740000492.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000085/wk-form4_1740000492.xml","form_type":"4"}},{"id":325785,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-02-19T21:28:19.000Z","date":"2025-02-14","kind":"tax_withholding","planned":true,"acquired":false,"shares":1504,"price":463.46,"value":697043.84,"ownership":{"direct":true},"balance_after":19263,"source":{"system":"sec-edgar","filing":"0000875320-25-000085","document":"wk-form4_1740000492.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000085/wk-form4_1740000492.xml","form_type":"4"}},{"id":326070,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-02-14T21:10:17.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":4437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests in installments beginning on 02/24/2026."}],"balance_after":20767,"source":{"system":"sec-edgar","filing":"0000875320-25-000063","document":"wk-form4_1739567406.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000063/wk-form4_1739567406.xml","form_type":"4"}},{"id":326172,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-02-12T21:36:29.000Z","date":"2025-02-11","kind":"sale","planned":true,"acquired":false,"shares":3433,"price":459.87,"value":1578733.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr.  Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/13/2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr.  Biller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $459.87 (range $459.83 to $460.00)."}],"balance_after":16330,"source":{"system":"sec-edgar","filing":"0000875320-25-000039","document":"wk-form4_1739396180.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000039/wk-form4_1739396180.xml","form_type":"4"}},{"id":326171,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-02-12T21:36:29.000Z","date":"2025-02-10","kind":"tax_withholding","planned":true,"acquired":false,"shares":1632,"price":467.98,"value":763743.36,"ownership":{"direct":true},"balance_after":19763,"source":{"system":"sec-edgar","filing":"0000875320-25-000039","document":"wk-form4_1739396180.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000039/wk-form4_1739396180.xml","form_type":"4"}},{"id":326555,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-02-06T21:32:00.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":4744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025."}],"balance_after":21395,"source":{"system":"sec-edgar","filing":"0000875320-25-000014","document":"wk-form4_1738877513.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000014/wk-form4_1738877513.xml","form_type":"4"}},{"id":330266,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-10-03T20:12:15.000Z","date":"2024-10-02","kind":"sale","planned":true,"acquired":false,"shares":999,"price":461.66,"value":461198.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/13/2024."}],"balance_after":16651,"source":{"system":"sec-edgar","filing":"0000875320-24-000214","document":"wk-form4_1727986328.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000214/wk-form4_1727986328.xml","form_type":"4"}},{"id":330265,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-10-03T20:12:15.000Z","date":"2024-10-01","kind":"tax_withholding","planned":true,"acquired":false,"shares":630,"price":466.84,"value":294109.2,"ownership":{"direct":true},"balance_after":17650,"source":{"system":"sec-edgar","filing":"0000875320-24-000214","document":"wk-form4_1727986328.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000214/wk-form4_1727986328.xml","form_type":"4"}},{"id":340498,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-02-13T21:56:51.000Z","date":"2024-02-12","kind":"sale","planned":true,"acquired":false,"shares":1738,"price":418.77,"value":727822.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/27/2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Biller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $418.77 (range $418.76 to $418.82)."}],"balance_after":18280,"source":{"system":"sec-edgar","filing":"0000875320-24-000047","document":"wk-form4_1707861402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000047/wk-form4_1707861402.xml","form_type":"4"}},{"id":340497,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-02-13T21:56:51.000Z","date":"2024-02-09","kind":"tax_withholding","planned":true,"acquired":false,"shares":1588,"price":422.74,"value":671311.12,"ownership":{"direct":true},"balance_after":20018,"source":{"system":"sec-edgar","filing":"0000875320-24-000047","document":"wk-form4_1707861402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000047/wk-form4_1707861402.xml","form_type":"4"}},{"id":341079,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-02-08T21:28:57.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":4743,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Restricted stock unit award that vests in installments beginning on 02/17/2025."}],"balance_after":21606,"source":{"system":"sec-edgar","filing":"0000875320-24-000022","document":"wk-form4_1707427717.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000022/wk-form4_1707427717.xml","form_type":"4"}},{"id":341078,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-02-08T21:28:57.000Z","date":"2024-02-06","kind":"grant","planned":false,"acquired":true,"shares":6294,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on  02/06/2024 and the shares will vest in installments beginning on 02/10/2024."}],"balance_after":16863,"source":{"system":"sec-edgar","filing":"0000875320-24-000022","document":"wk-form4_1707427717.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000022/wk-form4_1707427717.xml","form_type":"4"}},{"id":345420,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-10-03T20:07:56.000Z","date":"2023-10-02","kind":"sale","planned":true,"acquired":false,"shares":610,"price":346.76,"value":211523.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/27/2023."}],"balance_after":10569,"source":{"system":"sec-edgar","filing":"0001209191-23-051408","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123051408/doc4.xml","form_type":"4"}},{"id":345419,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-10-03T20:07:56.000Z","date":"2023-09-29","kind":"tax_withholding","planned":true,"acquired":false,"shares":408,"price":350.72,"value":143093.76,"ownership":{"direct":true},"balance_after":11179,"source":{"system":"sec-edgar","filing":"0001209191-23-051408","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123051408/doc4.xml","form_type":"4"}},{"id":354159,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-02-03T21:39:56.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":6293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests in installments beginning on 02/10/2024."}],"balance_after":11587,"source":{"system":"sec-edgar","filing":"0001209191-23-006913","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123006913/doc4.xml","form_type":"4"}},{"id":357985,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-09-21T20:10:10.000Z","date":"2022-09-19","kind":"grant","acquired":true,"shares":5294,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests in installments beginning on 10/01/2022."}],"balance_after":5294,"source":{"system":"sec-edgar","filing":"0000899243-22-031641","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322031641/doc4.xml","form_type":"4"}},{"id":2355117,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock options (right to buy)","published_at":"2022-03-03T21:12:19.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":41000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 1, 2022. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":41000,"derivative":{"exercise_price":32.2,"expiration_date":"2032-03-01","underlying":"Common stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0001439222-22-000031","document":"wf-form4_164634191545873.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922222000031/wf-form4_164634191545873.xml","form_type":"4"}},{"id":2355116,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2022-03-03T21:12:19.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":11500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on  March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on  March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":11500,"derivative":{"underlying":"Common stock","underlying_shares":11500},"source":{"system":"sec-edgar","filing":"0001439222-22-000031","document":"wf-form4_164634191545873.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922222000031/wf-form4_164634191545873.xml","form_type":"4"}},{"id":2378777,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance share units","published_at":"2022-02-23T21:10:52.000Z","date":"2022-02-18","kind":"exercise","acquired":false,"shares":8523,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":8522,"derivative":{"underlying":"Common stock","underlying_shares":8523},"source":{"system":"sec-edgar","filing":"0001439222-22-000018","document":"wf-form4_164565063350307.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922222000018/wf-form4_164565063350307.xml","form_type":"4"}},{"id":2378776,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2022-02-23T21:10:52.000Z","date":"2022-02-22","kind":"tax_withholding","acquired":false,"shares":2688,"price":29.08,"value":78167.04,"ownership":{"direct":true},"balance_after":22953,"source":{"system":"sec-edgar","filing":"0001439222-22-000018","document":"wf-form4_164565063350307.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922222000018/wf-form4_164565063350307.xml","form_type":"4"}},{"id":2378775,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2022-02-23T21:10:52.000Z","date":"2022-02-18","kind":"exercise","acquired":true,"shares":8523,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":25641,"source":{"system":"sec-edgar","filing":"0001439222-22-000018","document":"wf-form4_164565063350307.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922222000018/wf-form4_164565063350307.xml","form_type":"4"}},{"id":2398233,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2022-02-14T21:08:09.000Z","date":"2022-02-10","kind":"exercise","acquired":false,"shares":3667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":7333,"derivative":{"underlying":"Common stock","underlying_shares":3667},"source":{"system":"sec-edgar","filing":"0001439222-22-000006","document":"wf-form4_164487285754334.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922222000006/wf-form4_164487285754334.xml","form_type":"4"}},{"id":2398232,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2022-02-14T21:08:09.000Z","date":"2022-02-10","kind":"tax_withholding","acquired":false,"shares":1349,"price":31.425,"value":42392.325,"ownership":{"direct":true},"balance_after":17118,"source":{"system":"sec-edgar","filing":"0001439222-22-000006","document":"wf-form4_164487285754334.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922222000006/wf-form4_164487285754334.xml","form_type":"4"}},{"id":2398231,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2022-02-14T21:08:09.000Z","date":"2022-02-10","kind":"exercise","acquired":true,"shares":3667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":18467,"source":{"system":"sec-edgar","filing":"0001439222-22-000006","document":"wf-form4_164487285754334.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922222000006/wf-form4_164487285754334.xml","form_type":"4"}},{"id":2482352,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2021-12-07T21:18:35.000Z","date":"2021-12-03","kind":"exercise","acquired":false,"shares":5753,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on December 3, 2019. Beginning on December 3, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on December 3, 2019. Beginning on December 3, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":5753,"derivative":{"underlying":"Common stock","underlying_shares":5753},"source":{"system":"sec-edgar","filing":"0001439222-21-000076","document":"wf-form4_163891189929319.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922221000076/wf-form4_163891189929319.xml","form_type":"4"}},{"id":2482351,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2021-12-07T21:18:35.000Z","date":"2021-12-03","kind":"tax_withholding","acquired":false,"shares":1823,"price":35.8781,"value":65405.7763,"ownership":{"direct":true},"balance_after":14800,"source":{"system":"sec-edgar","filing":"0001439222-21-000076","document":"wf-form4_163891189929319.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922221000076/wf-form4_163891189929319.xml","form_type":"4"}},{"id":2482350,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2021-12-07T21:18:35.000Z","date":"2021-12-03","kind":"exercise","acquired":true,"shares":5753,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 830 shares purchased through the Company's employee stock purchase plan."}],"balance_after":16623,"source":{"system":"sec-edgar","filing":"0001439222-21-000076","document":"wf-form4_163891189929319.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922221000076/wf-form4_163891189929319.xml","form_type":"4"}},{"id":2863622,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-02-12T21:22:26.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 10, 2021. The shares underlying this option vest as to 25% of the underlying shares on February 10, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":44000,"derivative":{"exercise_price":56.68,"expiration_date":"2031-02-10","underlying":"Common stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001439222-21-000004","document":"wf-form4_161316492476489.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922221000004/wf-form4_161316492476489.xml","form_type":"4"}},{"id":2863621,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2021-02-12T21:22:26.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":11000,"derivative":{"underlying":"Common stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001439222-21-000004","document":"wf-form4_161316492476489.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922221000004/wf-form4_161316492476489.xml","form_type":"4"}},{"id":2955313,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2020-12-07T23:21:46.000Z","date":"2020-12-03","kind":"exercise","acquired":false,"shares":5753,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on December 3, 2019. Beginning on December 3, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on December 3, 2019. Beginning on December 3, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":11506,"derivative":{"underlying":"Common stock","underlying_shares":5753},"source":{"system":"sec-edgar","filing":"0001439222-20-000071","document":"wf-form4_160738329299398.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922220000071/wf-form4_160738329299398.xml","form_type":"4"}},{"id":2955312,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2020-12-07T23:21:46.000Z","date":"2020-12-03","kind":"tax_withholding","acquired":false,"shares":1707,"price":45.87,"value":78300.09,"ownership":{"direct":true},"balance_after":10040,"source":{"system":"sec-edgar","filing":"0001439222-20-000071","document":"wf-form4_160738329299398.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922220000071/wf-form4_160738329299398.xml","form_type":"4"}},{"id":2955311,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2020-12-07T23:21:46.000Z","date":"2020-12-03","kind":"exercise","acquired":true,"shares":5753,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":11747,"source":{"system":"sec-edgar","filing":"0001439222-20-000071","document":"wf-form4_160738329299398.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922220000071/wf-form4_160738329299398.xml","form_type":"4"}},{"id":3176564,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Performance share units","published_at":"2020-04-15T20:27:03.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":8523,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service.  The performance criteria for the specified commercial milestone was determined to have been met on April 13, 2020, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date.  Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service.  The performance criteria for the specified commercial milestone was determined to have been met on April 13, 2020, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date.  Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":17045,"derivative":{"underlying":"Common stock","underlying_shares":8523},"source":{"system":"sec-edgar","filing":"0001439222-20-000032","document":"wf-form4_158698240592447.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922220000032/wf-form4_158698240592447.xml","form_type":"4"}},{"id":3176563,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common stock","published_at":"2020-04-15T20:27:03.000Z","date":"2020-04-14","kind":"tax_withholding","acquired":false,"shares":2529,"price":40.64,"value":102778.56,"ownership":{"direct":true},"balance_after":5994,"source":{"system":"sec-edgar","filing":"0001439222-20-000032","document":"wf-form4_158698240592447.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922220000032/wf-form4_158698240592447.xml","form_type":"4"}},{"id":3176562,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common stock","published_at":"2020-04-15T20:27:03.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":8523,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":8523,"source":{"system":"sec-edgar","filing":"0001439222-20-000032","document":"wf-form4_158698240592447.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922220000032/wf-form4_158698240592447.xml","form_type":"4"}},{"id":3351092,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted stock units","published_at":"2019-12-05T21:07:50.000Z","date":"2019-12-03","kind":"grant","acquired":true,"shares":17259,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on December 3, 2019. Beginning on December 3, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on December 3, 2019. Beginning on December 3, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":17259,"derivative":{"underlying":"Common stock","underlying_shares":17259},"source":{"system":"sec-edgar","filing":"0001439222-19-000028","document":"wf-form4_157558005250284.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922219000028/wf-form4_157558005250284.xml","form_type":"4"}},{"id":3351091,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-12-05T21:07:50.000Z","date":"2019-12-03","kind":"grant","acquired":true,"shares":78824,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 3, 2019. The shares underlying this option vest as to 25% of the underlying shares on December 3, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":78824,"derivative":{"exercise_price":39.11,"expiration_date":"2029-12-03","underlying":"Common stock","underlying_shares":78824},"source":{"system":"sec-edgar","filing":"0001439222-19-000028","document":"wf-form4_157558005250284.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744749/000143922219000028/wf-form4_157558005250284.xml","form_type":"4"}},{"id":3362069,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:12.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":31714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":31714},"source":{"system":"sec-edgar","filing":"0001415889-19-001374","document":"form4-11222019_071100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001374/form4-11222019_071100.xml","form_type":"4"}},{"id":3362068,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:12.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":6288,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6288},"source":{"system":"sec-edgar","filing":"0001415889-19-001374","document":"form4-11222019_071100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001374/form4-11222019_071100.xml","form_type":"4"}},{"id":3362067,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:12.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001415889-19-001374","document":"form4-11222019_071100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001374/form4-11222019_071100.xml","form_type":"4"}},{"id":3362066,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:12.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":781,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":781},"source":{"system":"sec-edgar","filing":"0001415889-19-001374","document":"form4-11222019_071100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001374/form4-11222019_071100.xml","form_type":"4"}},{"id":3362065,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:12.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":6719,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6719},"source":{"system":"sec-edgar","filing":"0001415889-19-001374","document":"form4-11222019_071100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001374/form4-11222019_071100.xml","form_type":"4"}},{"id":3362064,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:12.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":1563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1563},"source":{"system":"sec-edgar","filing":"0001415889-19-001374","document":"form4-11222019_071100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001374/form4-11222019_071100.xml","form_type":"4"}},{"id":3362063,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:12.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":4687,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights (\"CVRs\"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":88.91,"expiration_date":"2028-07-30","underlying":"Common Stock","underlying_shares":4687},"source":{"system":"sec-edgar","filing":"0001415889-19-001374","document":"form4-11222019_071100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001374/form4-11222019_071100.xml","form_type":"4"}},{"id":3362168,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":19646,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":79.51,"expiration_date":"2028-07-02","underlying":"Common Stock","underlying_shares":19646},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362167,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":4688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":83.13,"expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":4688},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362166,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":3437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":103.26,"expiration_date":"2028-01-29","underlying":"Common Stock","underlying_shares":3437},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362165,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":3438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":100.97,"expiration_date":"2027-10-30","underlying":"Common Stock","underlying_shares":3438},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362164,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":135.41,"expiration_date":"2027-07-31","underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362163,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":124.06,"expiration_date":"2027-05-01","underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362162,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":113.18,"expiration_date":"2027-01-30","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362161,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":102.18,"expiration_date":"2026-10-31","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362160,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":114.69,"expiration_date":"2026-08-01","underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362159,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":2344,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":104.97,"expiration_date":"2026-05-02","underlying":"Common Stock","underlying_shares":2344},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362158,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":2344,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":100.8,"expiration_date":"2026-02-01","underlying":"Common Stock","underlying_shares":2344},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362157,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":114.08,"expiration_date":"2025-11-09","underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362156,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":132.56,"expiration_date":"2025-07-27","underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362155,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":109.9,"expiration_date":"2025-05-04","underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362154,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":118.57,"expiration_date":"2025-02-02","underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362153,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":117.18,"expiration_date":"2024-12-19","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362152,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":1563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":103.1,"expiration_date":"2024-10-27","underlying":"Common Stock","underlying_shares":1563},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362151,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":1563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":87.64,"expiration_date":"2024-07-28","underlying":"Common Stock","underlying_shares":1563},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362150,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":1564,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":74.3,"expiration_date":"2024-02-03","underlying":"Common Stock","underlying_shares":1564},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362149,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":81.56,"expiration_date":"2023-12-02","underlying":"Common Stock","underlying_shares":726},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362148,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":1564,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":78.12,"expiration_date":"2023-10-28","underlying":"Common Stock","underlying_shares":1564},"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362147,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Common Stock","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":400,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects disposition in connection with the Merger Agreement.  Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362146,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Common stock","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":478,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"401(k)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects disposition in connection with the Merger Agreement.  Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362145,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Common Stock","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":26652,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects disposition in connection with the Merger Agreement.  Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3362144,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Common Stock","published_at":"2019-11-22T07:31:08.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":20387,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS.  These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the \"Effective Time\").  In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights (\"CVRs\") in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":26652,"source":{"system":"sec-edgar","filing":"0001415889-19-001373","document":"form4-11222019_071155.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001373/form4-11222019_071155.xml","form_type":"4"}},{"id":3382734,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Restricted Stock Unit","published_at":"2019-11-04T16:05:14.000Z","date":"2019-10-31","kind":"exercise","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units granted to the reporting person on October 31, 2016 have vested and settled for shares of the Company's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units granted to the reporting person on October 31, 2016 have vested and settled for shares of the Company's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units granted to the reporting person on October 31, 2016 have vested and settled for shares of the Company's common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0001415889-19-001254","document":"form4-11042019_041101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001254/form4-11042019_041101.xml","form_type":"4"}},{"id":3382733,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Common Stock","published_at":"2019-11-04T16:05:14.000Z","date":"2019-10-31","kind":"tax_withholding","acquired":false,"shares":1044,"price":108.03,"value":112783.32,"ownership":{"direct":true},"balance_after":6265,"source":{"system":"sec-edgar","filing":"0001415889-19-001254","document":"form4-11042019_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001254/form4-11042019_041101.xml","form_type":"4"}},{"id":3382732,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Common Stock","published_at":"2019-11-04T16:05:14.000Z","date":"2019-10-31","kind":"exercise","acquired":true,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units granted to the reporting person on October 31, 2016 have vested and settled for shares of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."}],"balance_after":7309,"source":{"system":"sec-edgar","filing":"0001415889-19-001254","document":"form4-11042019_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001254/form4-11042019_041101.xml","form_type":"4"}},{"id":3538559,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Restricted Stock Unit","published_at":"2019-05-06T16:05:14.000Z","date":"2019-05-02","kind":"exercise","acquired":false,"shares":1563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1563},"source":{"system":"sec-edgar","filing":"0001415889-19-000505","document":"form4-05062019_040501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919000505/form4-05062019_040501.xml","form_type":"4"}},{"id":3538558,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Common Stock","published_at":"2019-05-06T16:05:14.000Z","date":"2019-05-02","kind":"tax_withholding","acquired":false,"shares":490,"price":95.21,"value":46652.9,"ownership":{"direct":true},"balance_after":4184,"source":{"system":"sec-edgar","filing":"0001415889-19-000505","document":"form4-05062019_040501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919000505/form4-05062019_040501.xml","form_type":"4"}},{"id":3538557,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Common Stock","published_at":"2019-05-06T16:05:14.000Z","date":"2019-05-02","kind":"exercise","acquired":true,"shares":1563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."}],"balance_after":4674,"source":{"system":"sec-edgar","filing":"0001415889-19-000505","document":"form4-05062019_040501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919000505/form4-05062019_040501.xml","form_type":"4"}},{"id":3616282,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Restricted Stock Unit","published_at":"2019-03-05T16:05:24.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":31714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020.  Vested shares will be delivered to the reporting person promptly after the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020.  Vested shares will be delivered to the reporting person promptly after the vesting date."}],"balance_after":31714,"derivative":{"underlying":"Common Stock","underlying_shares":31714},"source":{"system":"sec-edgar","filing":"0001415889-19-000249","document":"form4-03052019_040312.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919000249/form4-03052019_040312.xml","form_type":"4"}},{"id":3728066,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Restricted Stock Unit","published_at":"2018-12-18T18:45:35.000Z","date":"2018-12-16","kind":"exercise","acquired":false,"shares":1900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1900},"source":{"system":"sec-edgar","filing":"0001415889-18-001776","document":"form4-12182018_031220.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918001776/form4-12182018_031220.xml","form_type":"4"}},{"id":3728065,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Common Stock","published_at":"2018-12-18T18:45:35.000Z","date":"2018-12-16","kind":"tax_withholding","acquired":false,"shares":935,"price":68.2,"value":63767.0,"ownership":{"direct":true},"balance_after":3111,"source":{"system":"sec-edgar","filing":"0001415889-18-001776","document":"form4-12182018_031220.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918001776/form4-12182018_031220.xml","form_type":"4"}},{"id":3728064,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Common Stock","published_at":"2018-12-18T18:45:35.000Z","date":"2018-12-16","kind":"exercise","acquired":true,"shares":1900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."}],"balance_after":4046,"source":{"system":"sec-edgar","filing":"0001415889-18-001776","document":"form4-12182018_031220.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918001776/form4-12182018_031220.xml","form_type":"4"}},{"id":3857252,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP AND GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2018-08-01T16:05:32.000Z","date":"2018-07-30","kind":"grant","acquired":true,"shares":4687,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was issued pursuant to the Company's 2017 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option is immediately exercisable and will vest in four equal annual installments commencing on July 30, 2019."}],"balance_after":4687,"derivative":{"exercise_price":88.91,"expiration_date":"2028-07-30","underlying":"Common Stock","underlying_shares":4687},"source":{"system":"sec-edgar","filing":"0001415889-18-001203","document":"form4-08012018_040815.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918001203/form4-08012018_040815.xml","form_type":"4"}}]}